Article
Daptomycin. Fresh from the Pipeline
Nature Reviews Drug Discovery
Document Type
Article
Publication Date
12-1-2003
Disciplines
Abstract
In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?
Citation Information
Aarti Raja, J. LaBonte, J. Lebbos and P. Kirkpatrick. "Daptomycin. Fresh from the Pipeline" Nature Reviews Drug Discovery (2003) ISSN: 1474-1776 Available at: http://works.bepress.com/aarti-raja/5/